Log in

OTCMKTS:REPRRepro-Med Systems Stock Price, Forecast & News

$9.07
+0.40 (+4.61 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.60
Now: $9.07
$9.14
50-Day Range
$6.31
MA: $9.47
$12.38
52-Week Range
$1.35
Now: $9.07
$4.26
Volume426,889 shs
Average Volume36,047 shs
Market Capitalization$361.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:REPR
CUSIPN/A
Phone845-469-2042

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.35 million
Cash Flow$0.07 per share
Book Value$0.23 per share

Profitability

Net Income$910,000.00

Miscellaneous

Employees75
Market Cap$361.78 million
Next Earnings DateN/A
OptionableNot Optionable

Receive REPR News and Ratings via Email

Sign-up to receive the latest news and ratings for REPR and its competitors with MarketBeat's FREE daily newsletter.

Repro-Med Systems (OTCMKTS:REPR) Frequently Asked Questions

How has Repro-Med Systems' stock been impacted by COVID-19 (Coronavirus)?

Repro-Med Systems' stock was trading at $8.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPR shares have increased by 5.2% and is now trading at $9.07. View which stocks have been most impacted by Coronavirus.

How were Repro-Med Systems' earnings last quarter?

Repro-Med Systems, Inc. (OTCMKTS:REPR) released its quarterly earnings data on Tuesday, August, 6th. The company reported $0.00 EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.02. The firm earned $5.35 million during the quarter. Repro-Med Systems had a return on equity of 7.63% and a net margin of 0.17%. View Repro-Med Systems' earnings history.

Has Repro-Med Systems been receiving favorable news coverage?

News articles about REPR stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Repro-Med Systems earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Repro-Med Systems.

Who are some of Repro-Med Systems' key competitors?

What other stocks do shareholders of Repro-Med Systems own?

Who are Repro-Med Systems' key executives?

Repro-Med Systems' management team includes the following people:
  • Mr. Daniel S. Goldberger, Exec. Chairman (Age 60)
  • Mr. Donald B. Pettigrew, CEO, Pres & Chief Commercial Officer (Age 51)
  • Ms. Karen Fisher, CFO, Treasurer & Corp. Sec. (Age 53)
  • Mr. Manuel A. Marques, Chief Operating Officer (Age 46)
  • Mr. Steven Kamphausen, Global VP of Sales & Marketing

What is Repro-Med Systems' stock symbol?

Repro-Med Systems trades on the OTCMKTS under the ticker symbol "REPR."

How do I buy shares of Repro-Med Systems?

Shares of REPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Repro-Med Systems' stock price today?

One share of REPR stock can currently be purchased for approximately $9.07.

How big of a company is Repro-Med Systems?

Repro-Med Systems has a market capitalization of $361.78 million and generates $17.35 million in revenue each year. Repro-Med Systems employs 75 workers across the globe.

What is Repro-Med Systems' official website?

The official website for Repro-Med Systems is www.rmsmedicalproducts.com.

How can I contact Repro-Med Systems?

Repro-Med Systems' mailing address is 24 CARPENTER RD, CHESTER NY, 10918. The company can be reached via phone at 845-469-2042 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.